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This editorial review summarizes the results of 5 meetings sponsored by the International Society for
Cutaneous Lymphoma at which the clinicopathologic and ancillary features of early mycosis fungoides
were critically examined. Based on this analysis, an algorithm was developed for the diagnosis of early
mycosis fungoides involving a holistic integration of clinical, histopathologic, immunopathologic, and
molecular biological characteristics. A novel aspect of this algorithm is that it relies on multiple types of
criteria rather than just one, for example, histopathology. Before its finalization, the proposed diagnostic
algorithm will require validation and possibly further refinement at multiple centers during the next
several years. It is anticipated that a more standardized approach to the diagnosis of early mycosis
fungoides will have a beneficial impact on the epidemiology, prognostication, treatment, and analysis
of clinical trials pertaining to this most common type of cutaneous lymphoma. ( J Am Acad Dermatol
2005;53:1053-63.)T
he early diagnosis of mycosis fungoides
(MF), the major subtype of cutaneous T-cell
lymphoma (CTCL), has important ramifica-
tions for therapeutic options, determination of prog-
nosis, and outcomes in clinical trials. However, the
diagnosis of MF in its patch or early plaque phase
is often difficult, either because of overlapping
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disease.
Recognizing this persistent need to develop
standardized diagnostic criteria for early MF, the
International Society for Cutaneous Lymphoma
(ISCL) sponsored meetings in Zurich, Switzerland
on May 28-31, 1999; in Napa, California on March 9,
2000; in Bethesda, Maryland on March 1, 2001; in
New Orleans, Louisiana on Feb 21, 2002; and in
Washington, DC on Feb 5, 2004 with the following
goals: (1) to facilitate discussion on this topic among
clinicians and scientists with extensive experience
in CTCL; (2) to develop a working proposal for
diagnostic criteria for early MF, taking into account
clinical, histologic, and ancillary (particularly immu-
nophenotypic and genotypic) criteria; and (3) to test
the validity of these criteria in an international
collaborative forum. We are confident that meeting
these goals will help to better evaluate the true
incidence of MF, to potentially discriminate among
prognostic subsets of MF, to advance the under-
standing of factors involved in the pathogenesis of
MF and its progression, and to aid in the development
of differential therapeutic approaches likely to im-
prove current remission and survival rates. The
meetings noted above accomplished the first goal.
This article summarizing the meetings’ proceedings
addresses the second goal and creates a framework
for achieving the third objective through future col-
laborative studies.
RELATIONSHIP BETWEEN MF AND
PARAPSORIASIS EN PLAQUES:
HISTORICAL PERSPECTIVE AND
CURRENT IMPLICATIONS
Part of the difficulty in establishing threshold
criteria for the diagnosis of early MF stems from the
existence of established terminology for reputedly
benign dermatoses, such as parapsoriasis en plaques
(PEP), that have overlapping clinical and/or histo-
logic features with early MF. By utilizing clinical
findings only, PEP was defined by Brocq1 in 1902
as a chronic, recurrent, erythematous, and scaling
Abbreviations used:
CI: confidence interval
CTCL: cutaneous T-cell lymphoma
DGGE: denaturing gradient gel electrophoresis
ISCL: International Society for Cutaneous
Lymphoma
MF: mycosis fungoides
OR: odds ratio
PCR: polymerase chain reaction
PEP: parapsoriasis en plaquesdermatosis that was part of a larger spectrum of
eczematoid, psoriasiform, or lichenoid skin disor-
ders (‘‘les parapsoriasis’’) whose nosology has been
reviewed elsewhere.2 The relation between PEP and
MF was first specifically addressed by Civatte3
(Brocq’s disciple) and other groups, including those
of Osmundsen,4 Samman,5 Bonvalet et al,6 and
Binazzi7 who made careful clinicopathologic cor-
relations from series of patients with PEP followed
over time. A ‘‘small’’ lesion variant, now commonly
termed small-plaque parapsoriasis, was distin-
guished from a ‘‘large’’ lesion variant, now referred
to as large plaque parapsoriasis, on the basis of size,
preferential distribution of lesions, and the presence
or absence of atrophy and/or poikiloderma.2 The
skin lesions of both small-plaque parapsoriasis and
large-plaque parapsoriasis are flat patches rather
than infiltrated plaques, consistent with the fact that
the French term plaque equates to the English term
patch. Therefore these two conditions would be
termed most appropriately ‘‘small-patch parapsoria-
sis’’ and ‘‘large-patch parapsoriasis,’’ except that these
terms incorporating the word ‘‘plaque’’ are embed-
ded in the literature.8,9
The lesions of small-plaque parapsoriasis are
generally on the upper trunk, sometimes with a
digitate appearance (so-called ‘‘digitate dermatosis’’)
and without atrophy or poikiloderma.2 Lesions are
usually 2 to 6 cm in diameter; however, the long axis
of digitate lesionsmay be up to 10 to 20 cm, imparting
a ‘‘fingermark’’ appearance. Histologically, small-
plaque parapsoriasis has been characterized by
nonspecific changes (focal spongiotic and/or psori-
asiform and/or lichenoid dermatitis with exocytosis
of small lymphocytes). Small-plaque parapsoriasis
has been judged to have little, if any, potential to
evolve to typical MF.8
In contrast, the lesions of large-plaque parapsori-
asis are usually larger than 6 cm in diameter and
localized to the buttocks, lower trunk, upper thighs,
inner upper arms, and inframammary areas (ie, non-
sun-exposed regions) and frequently manifest atro-
phy and/or poikiloderma. Histologically, the pattern
of lymphoid infiltration in large-plaque parapsori-
asis is similar to small-plaque parapsoriasis, but the
infiltrates often contain lymphocytes with cerebri-
form nuclei called Lutzner cells (synonymous with
Se´zary cells) similar to that seen in MF. Large-plaque
parapsoriasis has been long regarded to be difficult
to distinguish from patch-phase MF, with progres-
sion to frank MF in 7.5% to 14% of cases.2,5-7
In 1979, Sanchez and Ackerman10 suggested that
instead of large-plaque psoriasis evolving into frank
MF only in selected cases, large-plaque parapsoriasis
was synonymous with patch-stage MF. Ackerman
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small-plaque parapsoriasis in patients who also
had indubitable, biopsy-proven plaques of MF, thus
challenging that even small-plaque parapsoriasis
was always a benign dermatosis.11,12 Certainly, to
consider all parapsoriasis en plaques as early MF sim-
plified a common diagnostic dilemma, but it also
raised new problems in producing valid prognostic
survival information for patients with ‘‘early’’-stage
MF (information that drives the choice of therapy),
acceptable end points of therapy, interpretation of
response, and ultimately the generation of risk/
benefit ratios for different therapeutic interventions.
Moreover, the inclusion of patients with a ‘‘be-
nign’’ course into the mix of patients who have a
definite, potentially life-threatening cancer poses
added risks for patients: those with ‘‘benign’’ disease
are at risk of being treated with inappropriately
aggressive therapy and those with a potential for
progressive disease are at risk of being deprived of
more definitive therapy.
From an epidemiologic point of view, changes in
the histologic criteria that favor the diagnosis of early
MF instead of parapsoriasis en plaques may have
profound effects on disease incidence and progno-
sis. In the past 20 years, a clear-cut increase in the
incidence of MF and, in parallel, improved overall
survival time have been observed.13,14 It is unknown
to what degree these observations are the conse-
quence of a substantial modification of the histologic
criteria for the diagnosis of early MF, earlier biopsy of
unexplained dermatitis, or an increase in the envi-
ronmental or genetic influences that may affect the
true incidence of MF. These questions are similar
to those posed regarding ‘‘atypical nevi’’ and mela-
noma. Finally, the classification of small-plaque
parapsoriasis, particularly the digitate variant, as a
form of MF obscures the issue of whether small-
plaque parapsoriasis is one step along the path of
MF tumor progression or is truly an unrelated bio-
logic entity.8,9,15-17
EARLY DIAGNOSIS OF MF: THE ROLE OF
CLINICAL ASSESSMENT
The diagnosis of MF relies heavily on clinical
assessment, particularly in providing a supportive
history, confirming one of several typical or suspect
clinical presentations of MF and directing the choice
of the critical biopsy site(s). The clinical diagnosis
of MF may be difficult to make in patch- or early
plaque-phase disease because many of its clinical
features may also be found in benign inflammatory
diseases. However, certain findings are quite char-
acteristic of early MF and, when present, are helpful
in establishing the diagnosis. The ISCL Task Force forthe Clinical Definition of Early MF* has identified
several clinical criteria that it believes are most
important for recognizing classic MF at its initial
presentation (patch phase) (Table I).
A. History
The most important aspect of the medical history
as it pertains to the diagnosis of MF is the persistent
nature of the disease. In addition, MF lesions tend to
increase in size and number over time, although this
is not an invariable finding. Although topical corti-
costeroids have a salutary effect in MF18 and may
even clear very early lesions,19 the lesions of MF
typically either incompletely clear with topical cor-
ticosteroids and recur when therapy is discontinued
or continue to develop in untreated areas. Because
some drug-induced eruptions (reviewed in Gul,
Kilic, and Dursun20) may share both clinical and
light microscopic features with MF, a trial off of a
potentially offending drug may be indicated to
eliminate this possibility.
B. Morphology of lesions
The clinical presentation of classic patch-phase
MF is characterized by variability in the size, shape,
and color of individual lesions. Most MF patch
lesions are large ([5 cm in diameter). Uniformly
small (\3 cm in width), even though sometimes very
‘‘long’’ (up to 10 cm or more in length), digitate
lesions are uncommon in MF and would make one
suspect the ‘‘digitate dermatosis’’ variant of small-
plaque parapsoriasis. Untreated lesions of MF often
expand slowly to form well-demarcated lesions that
vary in size with or without coalescence and may
also undergo spontaneous clearing in areas. This
phenomenon of progression and regression of indi-
vidual lesions, when present, produces lesions that
are irregularly shaped.
Another important clinical feature that is relatively
specific for earlyMF is the presence of poikiloderma.2
Poikiloderma is defined clinically as the local juxta-
position of mottled pigmentation, telangiectasia, and
epidermal atrophy (cigarette paper wrinkling) inter-
spersed with slight infiltration. In some cases of MF,
there may be epidermal atrophy alone. Poikiloderma
may rarely be seen with the cutaneous lesions of
other subtypes of CTCL such as granulomatous
slack skin, the regressing lesions of anaplastic
*ISCL Task Force for the Clinical Definition of Early MF: Chair: Seth
Stevens, MD, Cleveland, Ohio; members: Peter Heald, MD, New
Haven, Conn; Robert Knobler, MD, Vienna, Austria; Elise A.
Olsen, MD, Durham, NC; Nicola Pimpinelli, MD, Florence, Italy;
Masahiro Takigawa, MD, Hamamatsu, Japan; Eric Vonderheid,
MD, Baltimore, Md.
J AM ACAD DERMATOL
DECEMBER 2005
1056 Pimpinelli et alT-cell lymphoma, connective tissue disease such as
dermatomyositis, and certain genodermatoses.
Poikiloderma is not a feature of atopic dermatitis,
nummular eczema, psoriasis, lichen planus, drug
eruptions, tinea corporis, erythema chronicum mi-
grans, small-plaque parapsoriasis/digitate derma-
tosis, pityriasis rosea, or other benign dermatoses
likely to be clinically confused with MF. Poikilo-
derma is, however, commonly seen with large-
plaque parapsoriasis, where it has been referred to
as poikiloderma vasculare atrophicans. Persistent
poikilodermatous patches on non-sun-exposed
skin, particularly the buttocks, should be considered
MF until proven otherwise by biopsy.
Table I. Algorithm for diagnosis of early MF*
Criteria Scoring system
Clinical
Basic 2 points for basic criteria
and two additional
criteria
Persistent and/or progressive
patches/thin plaques
1 point for basic criteria
and one additional
criterion
Additional
1) Non-sun exposed
location
2) Size/shape variation
3) Poikiloderma
Histopathologic
Basic 2 points for basic criteria
and two additional
criteria
Superficial lymphoid
infiltrate
1 point for basic criteria
and one additional
criterion
Additional
1) Epidermotropism
without spongiosis
2) Lymphoid atypiay
Molecular biological
1) Clonal TCR gene
rearrangement
1 point for clonality
Immunopathologic
1)\50% CD21, CD31,
and/or CD51 T cells
1 point for one or more
criteria
2)\10% CD71 T cells
3) Epidermal/dermal
discordance of CD2,
CD3, CD5, or CD7z
MF, Mycosis fungoides; TCR, T-cell receptor.
*A total of 4 points is required for the diagnosis of MF based on
any combination of points from the clinical, histopathologic,
molecular biological, and immunopathologic criteria.
yLymphoid atypia is defined as cells with enlarged hyperchromatic
nuclei and irregular or cerebriform nuclear contours.
zT-cell antigen deficiency confined to the epidermis.C. Number of lesions
Although MF may occur as a single lesion (unile-
sional MF),21-23 most patients with classic MF typi-
cally present with multiple lesions and several sites
of involvement. In particular, certain drugs may
lead to a fixed drug reaction and produce solitary
lesions that may be confused with unilesional MF.
Other disorders that might be confused with unile-
sional MF include nummular eczema, lichen simplex
chronicus, erythema chronicum migrans, and tinea
corporis.
D. Distribution of lesions
MF has a proclivity to develop initially on rela-
tively non-sun-exposed areas of the skin, such as the
trunk below the waistline (‘‘bathing suit’’ distribu-
tion), flanks, breasts, inner thighs, inner arms, and
periaxillary areas. This characteristic distribution
may be less apparent in dark-skinned patients.
However, lesions may appear on the face or scalp
early in the course of disease particularly if there is a
component of follicular involvement. Occasionally,
MF may present as a refractory dermatosis of the
palms or soles.24
EARLY DIAGNOSIS OF MF: THE ROLE
OF HISTOPATHOLOGY
The definition of histopathologic features to dif-
ferentiate early MF from benign inflammatory dis-
eases is by far the most difficult, debated, and yet
crucial issue. To enhance the chance of establishing a
histologic diagnosis of MF, multiple biopsies from a
variety of lesions may be required, including the
oldest, well-developed, most infiltrated lesions as
well as the newest lesions. With the exception of
emollients, it is important that all topical treatments,
but especially topical corticosteroids and systemic
immunosuppressants, be discontinued at least
2 to 4 weeks before performing a biopsy or else
the salient histologic features of MF may be
suppressed.
Several cytologic and architectural histopath-
ologic criteria, variably grouped to identify the
categories of ‘‘diagnostic of,’’ ‘‘consistent with,’’ and
‘‘suggestive of’’ MF, have been proposed in the past
two decades. These include the following:
1. Presence of atypical lymphoid cells that are
slightly larger than normal lymphocytes and
have hyperchromatic, irregularly contoured (con-
voluted) nuclei.25 Such cells have been variably
termed ‘‘mycosis cells,’’ ‘‘Lutzner cells,’’ or ‘‘Se´zary
cells.’’26
2. Presence of individual haloed atypical lympho-
cytes within the epidermis27
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ranged along the basal layer of the epidermis
with pagetoid spread (ie, buckshot distribution
with pericellular halos)10
4. Presence of an increased or skewed number of
lymphocytes (not necessarily atypical) relative to
typical dermatitis, distributed singly or in small
collections in an epidermis devoid of spongiotic
microvesiculation.10,28 The term ‘‘disproportion-
ate epidermotropism’’ has been used to express
this concept.
5. Presence of vacuolar interface dermatitis29
6. Presence of papillary dermal fibrosis10,27,28,30
In 2001, Guitart et al31 published an integrated
grading system, reflecting the pathologist’s degree of
diagnostic certainty, based on the sequential evalu-
ation of major criteria (density of the infiltrate,
evaluated at low power; nature and extent of epi-
dermotropism, evaluated at medium power; and
grade of lymphocytic atypia, evaluated at high
power), which were scored 0 to 3 points according
to the degree of their presence, and minor criteria
(presence of atypia primarily in the intraepidermal
compartment [low grade atypia:1 point; high grade:
2 points], lack of associated inflammatory features
[1 point], reticular/wiry fibroplasia within the papil-
lary dermis [1 point]). The diagnoses rendered under
this system were reached by adding the components
to obtain the total score and were specifically as
follows: (1) perivascular/interface lymphocytic der-
matitis (total score: 0-2 points); (2) atypical lympho-
cytic infiltrate (MF cannot be excluded) (total score:
3-4 points); (3) atypical lymphocytic infiltrate sug-
gestive of MF (total score: 5-6 points); and (4) MF
(total score 7).Within the confines of this study, there
was improvement shown with this approach (ie,
using histologic criteria and a training session for
evaluators) compared with independent assessment
alone. Specifically, there was an increase in the
agreement rate among pathologists as reflected by
an increase in overall precision weighted k values
from 0.630 to 0.854. However, as is true of all the
histopathologic studies to date, this method has not
been adopted widely or validated by others yet.
Nevertheless, two other studies warrant specific
mention because of their international nature.
In 2000, the European Organisation for Research
and Treatment of Cancer’s Cutaneous Lymphoma
Study Group addressed the issue of histologic defi-
nition of early MF by publishing a retrospective
review of 24 biopsy specimens obtained from
18 patients with limited patch-stage lesions whose
diagnosis of MF was based on clear-cut clinical and
histologic progression to more advanced diseaseover time.32 As controls, 13 biopsies of spongiotic,
lichenoid, or psoriasiform simulators of MF were
randomly intermixed with the 24 MF biopsies by a
participant uninvolved in the biopsy assessments.
The panel, composed of 3 physicians well trained in
the histopathology of lymphoproliferative disorders
(one dermatologist/dermatopathologist, one hema-
topathologist, and one pathologist experienced in
dermatopathology), used a multiheaded microscope
to review the slides together for the presence of a
large series of histologic criteria. They found that
the presence of medium-sized to large (7- to 9-m
nuclear diameter, ie, approximately the same diam-
eter as the nuclei of basal keratinocytes) cerebriform
mononuclear cells was the most important histologic
feature for the diagnosis of MF (multivariate log
linear analysis P \ .001). When these cells were
distributed either singly or in small clusters in the
epidermis, the sensitivity and specificity for the
diagnosis of MF were 100% and 92.3%, respectively.
When the cells were in clusters in the dermis, the
sensitivity and specificity were 91.7% and 100%,
respectively. Moreover, the absence of papillary
dermal fibrosis (66.7% sensitivity and 100% specific-
ity), the presence of epidermotropism with linearly
arranged single lymphoid cells (closely apposed to
basal keratinocytes and lined up along contiguous
rete ridges like a necklace on the epidermal side of
the derm0epidermal junction) (45.8% sensitivity and
100% specificity), and absence of dermal blast-like
cells (41.7% sensitivity and 100% specificity) were
found to yield additional independent diagnostic
information (multivariate log linear analysis P \
.001). Further evaluation is necessary to determine
whether these findings can be confirmed in larger
studies and in clinical practice or have predictive
value for progressive disease.
Finally, another attempt to reach an international
consensus about the histologic definition of early MF
was made with an ISCL-sponsored workshop held
in Zurich, Switzerland (May 28-31, 1999) devoted to
assessing a number of preselected potential histo-
logic criteria for the diagnosis of early MF. An
international panel of dermatopathologists with spe-
cific expertise in cutaneous lymphomas* indepen-
dently reviewed 33 MF cases, the diagnosis of which
had been conclusively confirmed with long-term
*ISCL Task Force on the Pathology of Early MF: Chairs: Marco
Santucci, MD, Florence, Italy; Bruce Smoller, MD, Little Rock, AK;
members: Guenter Burg, MD and Werner Kempf, MD, Zurich,
Switzerland; Lorenzo Cerroni, MD, Graz, Austria; Earl Glusac,
MD, New Haven, CT; Joan Guitart, MD, Chicago, IL; Christian
Sander, MD, Hamburg, Germany; Gladys Telang, MD, Philadel-
phia, PA.
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and 33 inflammatory disease controls. The findings
(unpublished data) were as follows:
d Lymphoid cells with variable nuclear and cyto-
plasmic features and/or with strikingly irregular
nuclear contours (53.3% sensitivity and 88.9%
specificity; odds ratio [OR] 9.14, 95% confidence
interval [CI] 3.16-26.49) and/or presence of lym-
phocytes larger than those usually seen in inflam-
matory dermatoses (36.7% sensitivity and 92.1%
specificity; OR 6.72, 95% CI 2.07-21.80) consti-
tuted the major criteria for the diagnosis of MF.
d Haloed lymphoid cells (13.3% sensitivity and
98.4% specificity; OR 9.54, 95% CI 1.02-89.48),
disproportionate epitheliotropism (36.7% sensitiv-
ity and 84.1% specificity; OR 3.07, 95% CI 1.12-
8.37), and presence of an epidermotropic, band-
like infiltrate of lymphocytes (50% sensitivity and
73% specificity; OR 2.71, 95% CI 1.09-6.70) were
documented to have a limited impact on the
diagnosis of MF.
d In this study of early MF, the finding of Pautrier
microabscesses, considered a highly specific cri-
terion in MF in general, did not reach statistical
significance (16.7% sensitivity, 92.1% specificity;
OR 2.95, 95% CI 0.73-11.91). Similarly, the pres-
ence of: (1) wiry bundles of collagen (papillary
dermal fibrosis), (2) lymphocytes in the epidermis
larger than those in the dermis, and (3) admixed
inflammatory cells (eg, eosinophils, plasma cells)
yielded negative results.
d Small-plaque parapsoriasis showed histologic fea-
tures indistinguishable from those of inflamma-
tory controls.
The multivariate analysis determined that the best
combination for the identification of MF was the
presence of lymphoid cells with variable nuclear and
cytoplasmic features and with striking irregular nu-
clear contours (log rank test = 22.08, P value = .000),
with a misclassification error rate of 21.51%. Adding
the other criteria, useful according to the univariate
analysis, did not improve the final results, that is, it
did not reduce the misclassification error rate. The
consensus was hampered, however, by the high
interobserver variability. The criterion-specific k for
statistically significant criteria ranged from 0.3762 to
0.4332, documenting a fair to moderate agreement
beyond chance.
EARLY DIAGNOSIS OF MF: THE ROLE OF
ANCILLARY TECHNIQUES
DNA cytophotometry,33-37 nuclear morphome-
try,38-41 immunohistochemistry,42-57 chromosomalstudies,58-60 and, more recently, molecular genetic
analysis of T-cell clonality8,55-57,61-78 have generated
a significant amount of data that suggest their utility
not only in the early diagnosis of MF but also
potentially in the clinical management of MF pa-
tients. How these data may be integrated with light
microscopy to aid in the definitive diagnosis of CTCL
has not been standardized. The ISCL Task Force on
the Role of Ancillary Techniques in the Diagnosis of
Early MF,* based on critical review of the literature
and the experience accumulated in different institu-
tions, has addressed these issues with the analysis
and conclusions detailed below.
Sensitivity and specificity are crucial issues in the
detection of T-cell anomalies in early MF. They
depend on several factors, including type of assay,
tissue processing, and selection of controls. In the
case of clonality, polymerase chain reaction (PCR)e
based assays are more sensitive than Southern blot
analysis (eg, 90% vs 59% in a direct comparison).63
The overall sensitivity of PCR methods varies from
60% to 100%. One recommended method utilizes
DNA extracted from fresh-frozen tissue and PCR-
based clonality analysis of T-cell receptor g gene
rearrangements using denaturing gradient gel elec-
trophoresis (PCR/DGGE). Alternative PCR assays
with a similar 1% clonal detection threshold are also
acceptable.79 Unpublished direct comparisons of
PCR/DGGE analysis of frozen versus formalin-fixed,
paraffin-embedded samples have shown both false-
positive and false-negative results in archival speci-
mens relative to fresh-frozen ones (Gary Wood,
unpublished data). Specificity has been as high as
100% but depends heavily on selection of controls;
several clinically benign skin diseases, such as
lymphomatoid papulosis and pityriasis lichenoides,
can show dominant clonality in at least some
cases and should be excluded from assessments of
specificity.62,63
The detection of a clonal T-cell population by
sensitive PCR techniques on frozen specimens that
otherwise do not have diagnostic histopathologic
features of MF has generated the concepts of
‘‘clonal dermatitis’’62,63 and/or ‘‘abortive/latent lym-
phoma.’’8,15,17 Long-term follow-up of patients cate-
gorized as having ‘‘clonal dermatitis’’ indicates that
progression to overtMF occurs at a rate thatmay be as
much as 4 times higher than that for large-plaque
*ISCL Task Force on the Role of Ancillary Techniques in Diagnosing
Early MF: Chair: Gary Wood, MD, Madison, Wis; members:
Brigitte Dreno, MD, Nantes, France; Andreas Haeffner, MD,
Zurich, Switzerland; Erik R. Obik (Hansen), MD, Aarhus, Den-
mark; Keiji Iwatsuki, MD, Okayama, Japan; J. Marcus Muche, MD,
Berlin, Germany; Sean Whittaker, MD, London, UK.
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alone.63,79 This suggests the existence of a specific
category of patients (those with clonal dermatitis)
who are at significant risk of progression to MF in the
absence of definite clinicopathologic features of MF.
In addition, recent studies stress the importance of
combining clinical features with the evidence of a
clone for the diagnosis of early MF.80 That the more
sensitive molecular studies may be able to unmask
this subset of ‘‘benign’’ dermatoses is supported by
studies showing clonal populations,81,82 aberrant
immunophenotypes,57 and/or MF-like T-cell cyto-
kine production profiles83 in the peripheral blood
of some patients diagnosed as ‘‘parapsoriasis en
plaques.’’ More recently developed techniques,
such as single-cell PCR combined with laser-assisted
microdissection, that exceed the current sensitivity
of PCR-based methods (;1% clonal detection thres-
hold)76,77 need further evaluation regarding their
specificity.
Among genetic studies, some previous reports60
indicate that both skin-homing T cells and peripheral
blood mononuclear cells of CTCL patients have high
telomerase activity and short telomere length com-
pared with healthy control subjects. In addition,
molecular cytogenetics using G-banding,59 compar-
ative genomic hybridization, multifluor fluorescence
in-situ hybridization, and cDNA microarrays84 have
been proposed as adjunctive diagnostic tools. The
possible role of these assays in the diagnostic defi-
nition of MF needs further evaluation. DNA flow
cytometry and morphometry of blood alone have
limited value in establishing an early diagnosis of MF.
The sensitivity and specificity for early MF of
immunopathologic criteria involving antigen defi-
ciencies also depend on multiple factors. These
include the precise definition of antigen deficiency,
tissue processing, primary antibody used, patient
age, and selection of controls.45,52,56,85-89 For frozen
tissue, primary antibodies Leu-9, B-B7, and 3A1 that
define CD7 have been used. The best sensitivity in
frozen sections (59%-88%) has been achieved with
Leu-9 and B-B7, with reported specificity of 87%-
98%. CD7-272 is the best marker for CD7 in paraffin
sections. In paraffin sections, CD7-272 has a sensi-
tivity of 81% and a specificity of 100%; however,
these results were based on a study that included
advanced as well as early cases of MF.88 The cut-
point for defining antigen deficiency has varied with
the particular antigen in question and the method of
quantitation. For total lesional infiltrates, CD2, CD3,
and CD5 expression by less than 50% of T cells is
virtually 100% specific for T-cell lymphoma but only
about 10% sensitive for MF. This is also true for
epidermal/dermal discordance for CD2, CD3, CD5,and CD7.90 Discordance refers to antigen deficiency
restricted to the epidermis. For total lesional infil-
trates, CD7 expression of less than 33% has been
reported to be 59% sensitive and 97% specific for
MF.85 CD7 expression of less than 10% has been
reported to be 41% sensitive and 100% specific for
MF,85 although larger unpublished experience sug-
gests that the specificity is closer to 80% (Gary Wood,
unpublished data).
The status of CD13,47 CD26, CD49d, and CD60
antigens91-93 and the possible role of T-cell receptor
V-beta repertoire analysis51,53 requires further study
at this time.
DIAGNOSTIC ALGORITHM: AN ISCL
PROPOSAL
Based on the literature reviewed herein, the pro-
ceedings of the ISCL meetings in Zurich, Napa,
Bethesda, New Orleans, and Washington, DC, as
well as our aggregate experience evaluating early
MF, we have proposed an algorithm for the diagnosis
of early ‘‘classic’’ MF that incorporates clinical,
histopathologic, molecular biologic, and immuno-
pathologic features (Table I). The diagnosis of early
MF requires a total of 4 points. Because molecular
biologic and immunopathologic criteria represent no
more than 1 point each, they always require addi-
tional clinical and/or histopathologic criteria to
establish the diagnosis of early MF. Conversely, if
sufficient clinical and histopathologic criteria aremet,
then molecular and immunopathologic criteria are
not necessary.
This algorithm represents a major departure from
several past proposals of criteria for diagnosing MF,
especially histopathologic ones, because there is no
undue reliance on any one type of criteria. This is a
crucial feature of this algorithm: it relies on up to 4
types of criteria, not just one. Because no single
criterion needs to stand alone, none has to be entirely
specific in and of itself. Furthermore, each criterion
canbe relatively simple and therefore reproducible in
both an interobserver and an intraobserver capacity.
This algorithm is intended to be used for 3 major
purposes: first, to define minimal diagnostic criteria
for general purposes of interinstitutional uniformity
needed for multicenter studies and comparison
among different studies; second, to aid diagnosis in
individual cases involving the commonpresentations
of early MF; and third, to aid in the diagnosis of
recurrent MF in patients previously in remission who
have new cutaneous lesions of uncertain origin.
Clinical criteria
To fulfill any of the clinical criteria, lesionsmust be
persistent and/or progressive patches/thin plaques
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features for 2 points or one of the following for
1 point:
d Non-sun-exposed location
d Size/shape variation or
d Poikiloderma.
Histopathologic criteria
To fulfill any of the histologic criteria, biopsy
specimens must first have a superficial lymphoid
infiltrate. Epidermotropism without spongiosis and
lymphoid atypia each qualify as 1 point. Atypia is
manifested as cells with enlarged, hyperchromatic
nuclei with irregular or cerebriform nuclear con-
tours. Note that these criteria are not entirely specific
for MF. For example, the criterion of epidermotro-
pism alone might be seen in collagen vascular
diseases. Epidermotropism and/or lymphoid atypia
might be seen in some drug-induced pseudolym-
phomas. Atypia might also be seen in lymphomatoid
contact dermatitis, a spongiotic simulant of MF.
However, the utility of the histopathologic criteria
is preserved by their interdependence on the other
criteria (clinical, molecular, and immunopathologic)
in order to achieve the 4 points needed to establish
the diagnosis of early MF. An important caveat is that
the overall clinicopathological features cannot sug-
gest a specific non-MF diagnosis.
Molecular biological criteria
To fulfill this criterion, a dominant T-cell clonal
pattern must be detected by PCR-based analysis of
T-cell receptor gene rearrangements. This is worth
1 point. The PCR/DGGE method (or a related tech-
nique such as PCR/temperature gradient gel electro-
phoresis or PCR/single stranded conformational
polymorphism analysis) is preferred because the
clonal detection threshold of these assays has been
determined to be approximately 1%, which is rea-
sonably sensitive and specific for early CTCL. In
contrast, methods like PCR/ribonuclease protection
analysis are too sensitive (clonal detection threshold
0.001%-0.01%) and could detect reactive, inflamma-
tory T-cell clones. Southern blot analysis is too
insensitive (clonal detection threshold 5%-20%) and
would fail to detect tumor clones in many cases of
early MF.79 Although the presence of a matching
clone in multiple skin lesions has shown a strong
association with eventual clear-cut evidence of MF,94
this can also occur in clonal dermatitis. Therefore
we did not make matching clones a criterion in
the algorithm. This avoids undue emphasis on
clonality.Immunopathologic criteria
Any one of 3 features must be present to generate
1 point: less than 50% of T cells expressing CD2, CD3,
and/or CD5; less than 10% of T cells expressing CD7;
or epidermal/dermal discordance for expression of
CD2, CD3, CD5, and/or CD7. The first and last of
these features are virtually 100% specific for T-cell
lymphoma but only about 10% sensitive for early
MF.45,85,89,90 CD7 deficiency is about 40% sensitive
and 80% specific based on the same literature and
our general experience.
Caveats concerning the algorithm
It is difficult if not impossible to create an algo-
rithm that is both straightforward and entirely spe-
cific for early MF. Nevertheless, its specificity will be
enhanced by recognition of the following points.
First, the algorithm is designed for classic presenta-
tions of early MF. It is not intended for atypical
clinical and histologic variants including follicular,
hypopigmented, purpuric, or palmoplantar MF.
They will require their own algorithms. Second,
regardless of any individual feature, if the overall
clinicopathologic correlation in a case suggests a
specific diagnosis other than MF, then the algorithm
ceases to apply. For example, this might occur in
some connective tissue diseases. In addition, some
drug-induced pseudo-MF lesions can closely mimic
true MF clinically, histopathologically, and in regard
to ancillary studies. Here the history is key. If the
history suggests a pseudo-MF drug eruption, then a
confirmatory trial off of the suspected medication
should be undertaken.
CONCLUSIONS
It is hoped that this proposed algorithmwill prove
useful in the standardization of the diagnosis of early
MF. Having such standardization is critical to pre-
dicting and tracking prognosis, designing clinical
trials, and implementing stage-appropriate treat-
ment. The ISCL has developed this algorithm only
as a first step toward establishing firm diagnostic
criteria for classic early MF (Table I). The next step
will be multicenter testing of this algorithm in order
to identify areas of weakness, refine the proposed
criteria, and validate its applicability. This will be
achieved initially by retrospective studies and later
by prospective analysis. Recently, cDNA microarrays
have demonstrated promise for the diagnosis of MF84
and Se´zary syndrome.95 However, issues of valida-
tion, availability, and cost will need to be resolved
before this method can gain widespread application
for the diagnosis of early MF.
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